Loading…

IGF-1 in gynaecology and obstetrics: update 2002

Recent discoveries on endocrine, paracrine and autocrine involvement of insulin-like growth factor-1 (IGF-1) in the proliferation of many tissues raised the attention of its role in reproduction and in the growth of various cancers as well as of benign proliferations. The intention of this article i...

Full description

Saved in:
Bibliographic Details
Published in:Maturitas 2002-04, Vol.41, p.65-83
Main Authors: Druckmann, R, Rohr, U.D
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c361t-da23e669f3b24979649a40e8dcea7960e8ea0e9835abe6511fdc7c3b0c908cf23
cites cdi_FETCH-LOGICAL-c361t-da23e669f3b24979649a40e8dcea7960e8ea0e9835abe6511fdc7c3b0c908cf23
container_end_page 83
container_issue
container_start_page 65
container_title Maturitas
container_volume 41
creator Druckmann, R
Rohr, U.D
description Recent discoveries on endocrine, paracrine and autocrine involvement of insulin-like growth factor-1 (IGF-1) in the proliferation of many tissues raised the attention of its role in reproduction and in the growth of various cancers as well as of benign proliferations. The intention of this article is to focus on IGF-1 in the field of gynaecology. Perimenopausal women who exhibit high IGF-1 and low IGF binding protein (IGFBP) levels, like IGFBG-3, have an increased risk of developing breast cancer. A higher risk for cervical, ovarian and endometrial cancer is related to high IGF-1 levels in post- and premenopausal women. It has been shown that myomas, by far the most common benign uterine tumor in women, grow in the presence of IGF-1, in vitro as well as in vivo. Studies show that IGF-1 is involved in the differentiation of various reproductive tissues, like endometrium and ovarian tissues. Patients suffering from polycystic ovary syndrome (PCO) frequently show insulin resistance accompanied by an increase of IGF-1 in plasma. Plasma IGF-1 levels are higher in cases of severe endometriosis, however, in endometriosis and in PCO IGF levels locally in the endometrium are reduced, what might explain infertility. Recently, it was shown that IGF facilitates the implantation of the human embryo in the endometrium during IVF. Implantation is a paradox where different immune systems have to collaborate to make implantation and survival of the pregnancy possible. IGF seems to be the starter molecule so that the two epithelia can fuse. A disturbance can result in complications during pregnancy i.e. spontaneous miscarriage, preeclampsia as well as defects of the embryo. Therefore, IGF is a useful marker in successful pregnancy as well. A better mechanistic understanding of IGF-1 action on the cellular level not only provides more elegant mechanistic explanations for the scientist, but the practitioner might find it interesting to utilize its diagnostic potential as a marker for various diseases. The relation between systemic IGF levels and local tissue IGF-1 levels has not yet been determined for all conditions.
doi_str_mv 10.1016/S0378-5122(02)00016-6
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71601577</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378512202000166</els_id><sourcerecordid>71601577</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-da23e669f3b24979649a40e8dcea7960e8ea0e9835abe6511fdc7c3b0c908cf23</originalsourceid><addsrcrecordid>eNqFkFFLwzAQx4Mobk4_gtIn0YfqXdOkrS8iw-lg4IP6HNLkOiJdO5tW2Lc3c0MfhcAlx-_uT36MnSPcIKC8fQWe5bHAJLmC5Bog9GJ5wMaYZzxOEfGQjX-RETvx_iNAAnh6zEaIhRBZIccM5k-zGCPXRMtNo8m0dbvcRLqxUVv6nvrOGX8XDWure4oSgOSUHVW69nS2rxP2Pnt8mz7Hi5en-fRhERsusY-tTjhJWVS8TNIiRKWFToFya0iHV7iRBipyLnRJUiBW1mSGl2AKyE2V8Am73O1dd-3nQL5XK-cN1bVuqB28ylACiiwLoNiBpmu976hS686tdLdRCGqrSv2oUlsPCsLZqlIyzF3sA4ZyRfZvau8mAPc7gMI3vxx1yhtHjSHrOjK9sq37J-IbtmB17Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71601577</pqid></control><display><type>article</type><title>IGF-1 in gynaecology and obstetrics: update 2002</title><source>ScienceDirect Freedom Collection</source><creator>Druckmann, R ; Rohr, U.D</creator><creatorcontrib>Druckmann, R ; Rohr, U.D</creatorcontrib><description>Recent discoveries on endocrine, paracrine and autocrine involvement of insulin-like growth factor-1 (IGF-1) in the proliferation of many tissues raised the attention of its role in reproduction and in the growth of various cancers as well as of benign proliferations. The intention of this article is to focus on IGF-1 in the field of gynaecology. Perimenopausal women who exhibit high IGF-1 and low IGF binding protein (IGFBP) levels, like IGFBG-3, have an increased risk of developing breast cancer. A higher risk for cervical, ovarian and endometrial cancer is related to high IGF-1 levels in post- and premenopausal women. It has been shown that myomas, by far the most common benign uterine tumor in women, grow in the presence of IGF-1, in vitro as well as in vivo. Studies show that IGF-1 is involved in the differentiation of various reproductive tissues, like endometrium and ovarian tissues. Patients suffering from polycystic ovary syndrome (PCO) frequently show insulin resistance accompanied by an increase of IGF-1 in plasma. Plasma IGF-1 levels are higher in cases of severe endometriosis, however, in endometriosis and in PCO IGF levels locally in the endometrium are reduced, what might explain infertility. Recently, it was shown that IGF facilitates the implantation of the human embryo in the endometrium during IVF. Implantation is a paradox where different immune systems have to collaborate to make implantation and survival of the pregnancy possible. IGF seems to be the starter molecule so that the two epithelia can fuse. A disturbance can result in complications during pregnancy i.e. spontaneous miscarriage, preeclampsia as well as defects of the embryo. Therefore, IGF is a useful marker in successful pregnancy as well. A better mechanistic understanding of IGF-1 action on the cellular level not only provides more elegant mechanistic explanations for the scientist, but the practitioner might find it interesting to utilize its diagnostic potential as a marker for various diseases. The relation between systemic IGF levels and local tissue IGF-1 levels has not yet been determined for all conditions.</description><identifier>ISSN: 0378-5122</identifier><identifier>EISSN: 1873-4111</identifier><identifier>DOI: 10.1016/S0378-5122(02)00016-6</identifier><identifier>PMID: 11955796</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Breast cancer ; Breast Neoplasms - genetics ; Diabetes ; Endometrial Neoplasms - genetics ; Endometriosis ; Endometriosis - genetics ; Female ; Genetic Predisposition to Disease ; Growth hormone ; Humans ; IGF-1 ; IGFBP ; Insulin ; Insulin-Like Growth Factor I - metabolism ; IVF ; Osteoporosis ; Ovarian Neoplasms - genetics ; PCO ; Polycystic Ovary Syndrome - genetics ; Risk Factors ; Women's Health</subject><ispartof>Maturitas, 2002-04, Vol.41, p.65-83</ispartof><rights>2002 Elsevier Science Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-da23e669f3b24979649a40e8dcea7960e8ea0e9835abe6511fdc7c3b0c908cf23</citedby><cites>FETCH-LOGICAL-c361t-da23e669f3b24979649a40e8dcea7960e8ea0e9835abe6511fdc7c3b0c908cf23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11955796$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Druckmann, R</creatorcontrib><creatorcontrib>Rohr, U.D</creatorcontrib><title>IGF-1 in gynaecology and obstetrics: update 2002</title><title>Maturitas</title><addtitle>Maturitas</addtitle><description>Recent discoveries on endocrine, paracrine and autocrine involvement of insulin-like growth factor-1 (IGF-1) in the proliferation of many tissues raised the attention of its role in reproduction and in the growth of various cancers as well as of benign proliferations. The intention of this article is to focus on IGF-1 in the field of gynaecology. Perimenopausal women who exhibit high IGF-1 and low IGF binding protein (IGFBP) levels, like IGFBG-3, have an increased risk of developing breast cancer. A higher risk for cervical, ovarian and endometrial cancer is related to high IGF-1 levels in post- and premenopausal women. It has been shown that myomas, by far the most common benign uterine tumor in women, grow in the presence of IGF-1, in vitro as well as in vivo. Studies show that IGF-1 is involved in the differentiation of various reproductive tissues, like endometrium and ovarian tissues. Patients suffering from polycystic ovary syndrome (PCO) frequently show insulin resistance accompanied by an increase of IGF-1 in plasma. Plasma IGF-1 levels are higher in cases of severe endometriosis, however, in endometriosis and in PCO IGF levels locally in the endometrium are reduced, what might explain infertility. Recently, it was shown that IGF facilitates the implantation of the human embryo in the endometrium during IVF. Implantation is a paradox where different immune systems have to collaborate to make implantation and survival of the pregnancy possible. IGF seems to be the starter molecule so that the two epithelia can fuse. A disturbance can result in complications during pregnancy i.e. spontaneous miscarriage, preeclampsia as well as defects of the embryo. Therefore, IGF is a useful marker in successful pregnancy as well. A better mechanistic understanding of IGF-1 action on the cellular level not only provides more elegant mechanistic explanations for the scientist, but the practitioner might find it interesting to utilize its diagnostic potential as a marker for various diseases. The relation between systemic IGF levels and local tissue IGF-1 levels has not yet been determined for all conditions.</description><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Diabetes</subject><subject>Endometrial Neoplasms - genetics</subject><subject>Endometriosis</subject><subject>Endometriosis - genetics</subject><subject>Female</subject><subject>Genetic Predisposition to Disease</subject><subject>Growth hormone</subject><subject>Humans</subject><subject>IGF-1</subject><subject>IGFBP</subject><subject>Insulin</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>IVF</subject><subject>Osteoporosis</subject><subject>Ovarian Neoplasms - genetics</subject><subject>PCO</subject><subject>Polycystic Ovary Syndrome - genetics</subject><subject>Risk Factors</subject><subject>Women's Health</subject><issn>0378-5122</issn><issn>1873-4111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqFkFFLwzAQx4Mobk4_gtIn0YfqXdOkrS8iw-lg4IP6HNLkOiJdO5tW2Lc3c0MfhcAlx-_uT36MnSPcIKC8fQWe5bHAJLmC5Bog9GJ5wMaYZzxOEfGQjX-RETvx_iNAAnh6zEaIhRBZIccM5k-zGCPXRMtNo8m0dbvcRLqxUVv6nvrOGX8XDWure4oSgOSUHVW69nS2rxP2Pnt8mz7Hi5en-fRhERsusY-tTjhJWVS8TNIiRKWFToFya0iHV7iRBipyLnRJUiBW1mSGl2AKyE2V8Am73O1dd-3nQL5XK-cN1bVuqB28ylACiiwLoNiBpmu976hS686tdLdRCGqrSv2oUlsPCsLZqlIyzF3sA4ZyRfZvau8mAPc7gMI3vxx1yhtHjSHrOjK9sq37J-IbtmB17Q</recordid><startdate>20020415</startdate><enddate>20020415</enddate><creator>Druckmann, R</creator><creator>Rohr, U.D</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020415</creationdate><title>IGF-1 in gynaecology and obstetrics: update 2002</title><author>Druckmann, R ; Rohr, U.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-da23e669f3b24979649a40e8dcea7960e8ea0e9835abe6511fdc7c3b0c908cf23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Diabetes</topic><topic>Endometrial Neoplasms - genetics</topic><topic>Endometriosis</topic><topic>Endometriosis - genetics</topic><topic>Female</topic><topic>Genetic Predisposition to Disease</topic><topic>Growth hormone</topic><topic>Humans</topic><topic>IGF-1</topic><topic>IGFBP</topic><topic>Insulin</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>IVF</topic><topic>Osteoporosis</topic><topic>Ovarian Neoplasms - genetics</topic><topic>PCO</topic><topic>Polycystic Ovary Syndrome - genetics</topic><topic>Risk Factors</topic><topic>Women's Health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Druckmann, R</creatorcontrib><creatorcontrib>Rohr, U.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Maturitas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Druckmann, R</au><au>Rohr, U.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IGF-1 in gynaecology and obstetrics: update 2002</atitle><jtitle>Maturitas</jtitle><addtitle>Maturitas</addtitle><date>2002-04-15</date><risdate>2002</risdate><volume>41</volume><spage>65</spage><epage>83</epage><pages>65-83</pages><issn>0378-5122</issn><eissn>1873-4111</eissn><abstract>Recent discoveries on endocrine, paracrine and autocrine involvement of insulin-like growth factor-1 (IGF-1) in the proliferation of many tissues raised the attention of its role in reproduction and in the growth of various cancers as well as of benign proliferations. The intention of this article is to focus on IGF-1 in the field of gynaecology. Perimenopausal women who exhibit high IGF-1 and low IGF binding protein (IGFBP) levels, like IGFBG-3, have an increased risk of developing breast cancer. A higher risk for cervical, ovarian and endometrial cancer is related to high IGF-1 levels in post- and premenopausal women. It has been shown that myomas, by far the most common benign uterine tumor in women, grow in the presence of IGF-1, in vitro as well as in vivo. Studies show that IGF-1 is involved in the differentiation of various reproductive tissues, like endometrium and ovarian tissues. Patients suffering from polycystic ovary syndrome (PCO) frequently show insulin resistance accompanied by an increase of IGF-1 in plasma. Plasma IGF-1 levels are higher in cases of severe endometriosis, however, in endometriosis and in PCO IGF levels locally in the endometrium are reduced, what might explain infertility. Recently, it was shown that IGF facilitates the implantation of the human embryo in the endometrium during IVF. Implantation is a paradox where different immune systems have to collaborate to make implantation and survival of the pregnancy possible. IGF seems to be the starter molecule so that the two epithelia can fuse. A disturbance can result in complications during pregnancy i.e. spontaneous miscarriage, preeclampsia as well as defects of the embryo. Therefore, IGF is a useful marker in successful pregnancy as well. A better mechanistic understanding of IGF-1 action on the cellular level not only provides more elegant mechanistic explanations for the scientist, but the practitioner might find it interesting to utilize its diagnostic potential as a marker for various diseases. The relation between systemic IGF levels and local tissue IGF-1 levels has not yet been determined for all conditions.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>11955796</pmid><doi>10.1016/S0378-5122(02)00016-6</doi><tpages>19</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5122
ispartof Maturitas, 2002-04, Vol.41, p.65-83
issn 0378-5122
1873-4111
language eng
recordid cdi_proquest_miscellaneous_71601577
source ScienceDirect Freedom Collection
subjects Breast cancer
Breast Neoplasms - genetics
Diabetes
Endometrial Neoplasms - genetics
Endometriosis
Endometriosis - genetics
Female
Genetic Predisposition to Disease
Growth hormone
Humans
IGF-1
IGFBP
Insulin
Insulin-Like Growth Factor I - metabolism
IVF
Osteoporosis
Ovarian Neoplasms - genetics
PCO
Polycystic Ovary Syndrome - genetics
Risk Factors
Women's Health
title IGF-1 in gynaecology and obstetrics: update 2002
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A44%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IGF-1%20in%20gynaecology%20and%20obstetrics:%20update%202002&rft.jtitle=Maturitas&rft.au=Druckmann,%20R&rft.date=2002-04-15&rft.volume=41&rft.spage=65&rft.epage=83&rft.pages=65-83&rft.issn=0378-5122&rft.eissn=1873-4111&rft_id=info:doi/10.1016/S0378-5122(02)00016-6&rft_dat=%3Cproquest_cross%3E71601577%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c361t-da23e669f3b24979649a40e8dcea7960e8ea0e9835abe6511fdc7c3b0c908cf23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71601577&rft_id=info:pmid/11955796&rfr_iscdi=true